Skip to content

DNBSEQ-T7+ — Complete Genomics (Swiss Rockets)

The refreshed DNB short-read flagship — 48B reads / 24h across four flow cells, $100 genome list, and a new corporate parent (Swiss Rockets) announced at AGBT 2026.

At a glance

  • Vendor / launch date / availability: Complete Genomics (announced at AGBT 2026); strategic license / acquisition by Swiss Rockets disclosed week of AGBT; shipping in US/Canada now per Complete Genomics AGBT 2026 PR and Swiss Rockets acquisition announcement.
  • Chemistry / modality: DNB (DNA nanoball) short-read SBS; four-flow-cell configuration.
  • Throughput (PR): 48 billion reads / 24h with four flow cells; ~28,000 30× human genomes per year per instrument per Complete Genomics AGBT 2026 PR (vendor PR — no independent benchmark).
  • Read length: Standard paired-end (2×150 and shorter PE configurations).
  • Accuracy (PR): Q40 per-base per Complete Genomics AGBT 2026 PR (vendor PR — no independent benchmark).
  • List price / cost-per-genome: $800k instrument; $100 / 30× human genome; $1 / Gb per Complete Genomics AGBT 2026 PR.

What's new vs prior generation

The "+" refresh is a throughput and accuracy bump on the existing DNBSEQ-T7 platform — pushing the four-flow-cell ceiling to 48B reads/24h and lifting per-base accuracy to a Q40 PR claim. The accompanying corporate change is the bigger headline: Swiss Rockets' announced license / acquisition restructures the route-to-market for MGI / Complete Genomics technology in regions where MGI has faced US import-restriction headwinds, providing the western commercial vehicle for the platform.

Headline benchmarks

Reception / competitive context

DNBSEQ-T7+ is the $100 / genome twin to Element VITARI ($689k list, $100 / genome) — the two are the AGBT 2026 short-read lineup's joint price floor, sitting below Ultima UG200 ($850k–$1.25M) and above Roche Axelios's $750k / $150 genome target. GenomeWeb's "battle royale" recap calls out the Swiss Rockets acquisition as the policy-relevant pivot that lets Complete Genomics compete in US clinical accounts that had been hesitant on MGI-branded hardware.

  • Downstream Bioconductor tools: short-read aligners (Rsubread, Rsamtools), VariantAnnotation, methylKit for methylation workflows.
  • Direct AGBT 2026 competitor: Element VITARI (matched $100 / genome list, slightly lower instrument cost).
  • Throughput tier above: Ultima UG200. Cost-per-genome tier below: Roche Axelios 1.
  • Corporate note: the Swiss Rockets license/acquisition reshapes the regional sales footprint and is worth flagging in cross-citations to MGI / BGI Genomics commentary.

Sources